MNMasanari Nishida

Masanari Nishida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masanari Nishida has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Masayuki Nagasawa

    Department of Urology, Shiga University of Medical Science, Otsu, Japan

    2 shared publications
  • Tetsuya Yoshida

    Department of Urology, Shiga University of Medical Science, Otsu, Japan

    2 shared publications
  • Akinori Wada

    Department of Urology, Shiga University of Medical Science, Otsu, Japan

    1 shared publication
  • Akinori Wada

    Department of Urology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga, 520-2192, Japan.

    1 shared publication
  • Akio Shimizu

    Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology (M.M.R.K., A. Sato, A. Shimizu, M.R.M., M.K., M.Z.N., M.N., H.O.), Shiga University of Medical Science, Otsu, Japan

    1 shared publication
  • Akira Sato

    Division of Molecular Medical Biochemistry, Department of Biochemistry and Molecular Biology, Shiga University of Medical Science, Japan

    1 shared publication

Latest Publications

  • Open Access

    Pulmonary tumor thrombotic microangiopathy associated with prostate cancer achieving over 10-year survival: a case report

    by Masanari Nishida, Masayuki Nagasawa, Yuji Sakano, Eiki Hanada, Akinori Wada, Tetsuya Yoshida, Susumu Kageyama

    Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare and often fatal pulmonary complication of malignancy, characterized by rapidly progressive pulmonary hypertension and difficulty in ante-mortem diagnosis. We report a case of PTTM associated with previously untreated metastatic prostate cancer in a 62-year-old man with an initial serum prostate-specific antigen level of 3,835 ng/mL and clinical stage cT3N0M1. 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed during the diagnostic workup revealed findings suggestive of pulmonary hypertension and right heart strain before the onset of overt respiratory failure. Shortly after prostate biopsy, the patient developed acute hypoxemic respiratory failure. Based on the clinical suspicion of PTTM, hormonal therapy was initiated promptly before pathological confirmation, resulting in rapid improvement of respiratory status. A definitive diagnosis of PTTM was subsequently established by pulmonary artery aspiration cytology obtained via right heart catheterization. The patient has remained alive for more than 10 years without recurrence of PTTM. This appears to represent the longest survival reported for PTTM to date. This case highlights the importance of early clinical suspicion and prompt cancer-directed therapy in patients with suspected PTTM.


  • Open Access

    Comparison of Surgical Outcomes Between the Hinotori and da Vinci Platforms in Robot‐Assisted Radical Prostatectomy: A Propensity Score‐Matched Study

    by Masanari Nishida, Akinori Wada, Tetsuya Yoshida, Kubota Shigehisa, Masayuki Nagasawa, Kenichi Kobayashi, Kazuaki Yamanaka, Kazuyoshi Johnin, Susumu Kageyama

    Introduction: Comparative evidence between robotic platforms for robot‐assisted radical prostatectomy (RARP) remains limited, particularly regarding oncological quality beyond perioperative outcomes. This study compared outcomes between the hinotori and da Vinci systems, focusing on positive surgical margin (PSM) distribution in a real‐world cohort with varying surgeon experience. Methods: We reviewed 437 patients who underwent RARP at our institution between 2013 and 2025. After propensity score matching, 130 patients in the da Vinci group and 65 in the hinotori group were analyzed. Perioperative outcomes, PSM rates and anatomical distribution, urinary continence recovery, and biochemical recurrence (BCR)‐free survival were compared. Results: The matched cohort involved 17 surgeons, including 12 hinotori surgeons, with expert surgeons performing 38% of hinotori procedures. Operative, console, and setup‐related times were longer, and estimated blood loss was greater in the hinotori group. No transfusions were required. Complication rates and hospital stay were comparable. No differences were observed in overall or stage‐specific PSM rates. PSMs most frequently involved the apex and posterolateral regions in both groups, with no difference in anatomical PSM distribution. The 12‐month urinary continence recovery rates were 87% in the hinotori group and 85% in the da Vinci group. In the 2‐year time‐aligned analysis, BCR‐free survival rates in the hinotori and da Vinci groups were 94% and 89% at 1 year and 89% and 85% at 2 years, respectively. Conclusion: Hinotori‐assisted RARP showed longer operative and setup‐related times but no apparent deterioration in perioperative safety, PSM outcomes including anatomical distribution, continence recovery, or early BCR‐free survival.

  • Afadin Promotes Vascular Smooth Muscle Cell Contraction by Interacting With Phospholipase C to Enhance Ca 2+ Signaling for Blood Pressure Regulation

    by Mahbubur Rahman Khan, Akira Sato, Akio Shimizu, Shunji Suetaka, Rasel Molla, Masahiro Komeno, Mst Zenika Nasrin, Masanari Nishida, Futoshi Toyoda, Munehito Arai, et al.

    BACKGROUND: Vascular smooth muscle cells (VSMCs) regulate vascular tone and blood pressure. Stimulation of VSMCs with vasoconstrictors, such as AngII (angiotensin II) or norepinephrine, activates the G-protein–coupled receptor–mediated cascade, leading to a hypercontractile state and vascular remodeling. Afadin, an intracellular adaptor protein that mainly localizes at cell-cell junctions, regulates various biological phenomena. However, its role in VSMCs remains unclear. METHODS: VSMCs were isolated from newly generated VSMC-specific afadin conditional knockout mice. A small peptide (7 amino acids) designed in silico to inhibit the afadin–PLC (phospholipase C) β association was administered to the mouse VSMCs and aortic media using adeno-associated virus. RESULTS: Unlike control mice, afadin conditional knockout mice did not exhibit AngII- or norepinephrine-induced elevation in blood pressure. VSMCs isolated from afadin conditional knockout mice were less responsive to AngII- or norepinephrine-induced cell contractility compared with control VSMCs, as evidenced by reduced release of intracellular Ca 2+ resulting from lowered production of AngII- or norepinephrine-induced inositol 1,4,5-trisphosphate. Mechanistically, the PDZ (disk large tumor suppressor, zonula occludens-1) domain of afadin was shown to associate with the C terminus of PLCβ, providing support for the localization of PLCβ on the plasma membrane, where it generates inositol 1,4,5-trisphosphate. Furthermore, the newly designed small peptide, which inhibited the afadin-PLCβ association, attenuated AngII-induced cell contractility and intracellular Ca 2+ release in vitro and blocked AngII-stimulated blood pressure elevation in vivo. CONCLUSIONS: Afadin expression in VSMCs promotes cell contraction by interacting with PLCβ to enhance Ca 2+ signaling and has potential as a novel molecular target for blood pressure regulation.